Tallac Therapeutics is focused on developing innovative cancer therapies through its proprietary platform of Toll-like Receptor Agonist Antibody Conjugates (TRAAC). This technology enables the precise conjugation of therapeutic oligonucleotide payloads, allowing for the systemic delivery of next-generation therapies, including TLR9 agonists like T-CpG. The lead candidate, TAC-001, is designed to selectively activate B cells by targeting the CD22 receptor, which is expressed on B cells, including those infiltrating tumors. This targeted approach aims to enhance immune responses within the tumor microenvironment, potentially leading to improved anti-tumor activity and better patient outcomes.

In addition to TAC-001, Tallac is advancing other TRAAC candidates, such as TAC-003, which targets Nectin-4, a cancer-associated antigen. Preclinical studies have shown that TAC-003 can activate immune cells and induce robust anti-tumor responses, particularly in cancers that express Nectin-4. The company’s approach leverages both innate and adaptive immunity to create therapies that may overcome resistance to existing treatments, with several candidates currently in various stages of clinical development. Overall, Tallac Therapeutics is pioneering a new class of immunotherapies that aim to enhance the efficacy of cancer treatments through targeted immune activation.

United States

Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.

Tallac Therapeutics

Company Details